Women with VVA often suffer from associated comorbidities, leading to increased utilization of healthcare resources. To determine if treating VVA leads to savings in costs, we undertook a retrospective analysis of the US claims-based MarketScan® Research Database.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2017 Published by Elsevier Inc.